Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer-Reference-Cited by-同舟云学术

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer

Published:2021-03-02 Issue:7 Volume:10 Page:2216-2231
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Shi Yunfei¹,Lei Youming¹,Liu Li²,Zhang Shiyue³,Wang Wenjing³,Zhao Juan³,Zhao Songhui³,Dong Xiaowei³,Yao Ming³^ORCID,Wang Kai³^ORCID,Zhou Qing⁴^ORCID

Affiliation:

1. Department of geriatric thoracic surgery The First Hospital of Kunming Medical University Kunming City People's Republic of China

2. Cancer Center Union HospitalTongji Medical CollegeHuazhong University of Science and Technology Wuhan People's Republic of China

3. OrigiMed Shanghai People's Republic of China

4. Guangdong Lung Cancer InstituteGuangdong Provincial Key Laboratory of Translational Medicine in Lung CancerGuangdong General Hospital and Guangdong Academy of Medical Sciences Guangzhou People's Republic of China

Funder

Kunming Medical University

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3649

Reference56 articles.

1. Cancer statistics in China, 2015

2. Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial